{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T01:16:22Z","timestamp":1784337382663,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T00:00:00Z","timestamp":1555545600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Incyte Corporation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1883-1","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T09:07:39Z","timestamp":1555578459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy"],"prefix":"10.1186","volume":"21","author":[{"given":"Kevin L.","family":"Winthrop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Clifton O.","family":"Bingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy J.","family":"Komocsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Klar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia E.","family":"Kartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,18]]},"reference":[{"key":"1883_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.semarthrit.2008.10.002","volume":"39","author":"DE Furst","year":"2010","unstructured":"Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010;39:327\u201346.","journal-title":"Semin Arthritis Rheum"},{"key":"1883_CR2","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","volume":"76","author":"S Ramiro","year":"2017","unstructured":"Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, Dougados M, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76:1101\u201336.","journal-title":"Ann Rheum Dis"},{"key":"1883_CR3","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1086\/587063","volume":"46","author":"T Gl\u00fcck","year":"2008","unstructured":"Gl\u00fcck T, M\u00fcller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis. 2008;46:1459\u201365.","journal-title":"Clin Infect Dis"},{"key":"1883_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:1\u201325.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1883_CR5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.7326\/M15-3005","volume":"164","author":"DK Kim","year":"2016","unstructured":"Kim DK, Bridges CB, Harriman KH. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older--United States, 2016. Ann Intern Med. 2016;164:184\u201394.","journal-title":"Ann Intern Med"},{"key":"1883_CR6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11926-014-0431-x","volume":"16","author":"LM Perry","year":"2014","unstructured":"Perry LM, Winthrop KL, Curtis JR. Vaccinations for rheumatoid arthritis. Curr Rheumatol Rep. 2014;16:431.","journal-title":"Curr Rheumatol Rep"},{"key":"1883_CR7","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","volume":"184","author":"JS Fridman","year":"2010","unstructured":"Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184:5298\u2013307.","journal-title":"J Immunol"},{"key":"1883_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","volume":"368","author":"JJ O'Shea","year":"2013","unstructured":"O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368:161\u201370.","journal-title":"N Engl J Med"},{"key":"1883_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76:88\u201395.","journal-title":"Ann Rheum Dis"},{"key":"1883_CR10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374:1243\u201352.","journal-title":"N Engl J Med"},{"key":"1883_CR11","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69:506\u201317.","journal-title":"Arthritis Rheumatol"},{"key":"1883_CR12","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652\u201362.","journal-title":"N Engl J Med"},{"key":"1883_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/art.25034","volume":"62","author":"CO Bingham III","year":"2010","unstructured":"Bingham CO III, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62:64\u201374.","journal-title":"Arthritis Rheum"},{"key":"1883_CR14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1128\/CVI.00735-14","volume":"22","author":"TM Daly","year":"2015","unstructured":"Daly TM, Hill HR. Use and clinical interpretation of pneumococcal antibody measurements in the evaluation of humoral immune function. Clin Vaccine Immunol. 2015;22:148\u201352.","journal-title":"Clin Vaccine Immunol"},{"key":"1883_CR15","unstructured":"Prevnar 13 [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc, a subsidiary of Pfizer. Inc; 2017."},{"key":"1883_CR16","unstructured":"Boostrix [package insert]. Rixensart, Belgium: GlaxoSmithkline biologicals. Marburg, Germany: GSK Vaccines GmbH; 2016."},{"key":"1883_CR17","unstructured":"CDC. 2018 Recommended immunizations for adults. \n                    https:\/\/www.cdc.gov\/vaccines\/schedules\/downloads\/adult\/adult-combined-schedule.pdf\n                    \n                  . Accessed 13 June 2018."},{"key":"1883_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s13075-015-0863-3","volume":"17","author":"K Migita","year":"2015","unstructured":"Migita K, Akeda Y, Akazawa M, Tohma S, Hirano F, Ideguchi H, et al. Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients. Arthritis Res Ther. 2015;17:357.","journal-title":"Arthritis Res Ther."},{"key":"1883_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/cid\/cix419","volume":"65","author":"AMM Deursen Van","year":"2017","unstructured":"Van Deursen AMM, van Houten MA, Webber C, Patton M, Scott DA, Patterson S, et al. Immunogenicity of the 13-valent pneumococcal conjugate vaccine in older adults with and without comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Clin Infect Dis. 2017;65:787\u201395.","journal-title":"Clin Infect Dis"},{"key":"1883_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jim.2018.08.002","volume":"461","author":"DC LaFon","year":"2018","unstructured":"LaFon DC, Nahm MH. Measuring immune responses to pneumococcal vaccines. J Immunol Methods. 2018;461:37\u201343.","journal-title":"J Immunol Methods"},{"key":"1883_CR21","first-page":"24","volume-title":"Vaccines","author":"CA Siegrist","year":"2013","unstructured":"Siegrist CA. Vaccine immunology. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: Suanders; 2013. p. 24.","edition":"6"},{"key":"1883_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016;75:687\u201395.","journal-title":"Ann Rheum Dis"},{"key":"1883_CR23","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/annrheumdis-2013-204427","volume":"74","author":"CO Bingham 3rd","year":"2015","unstructured":"Bingham CO 3rd, Rizzo W, Kivitz A, Hassanali A, Upmanyu R, Klearman M. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2015;74:818\u201322.","journal-title":"Ann Rheum Dis"},{"key":"1883_CR24","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jaad.2017.09.076","volume":"78","author":"KL Winthrop","year":"2018","unstructured":"Winthrop KL, Korman N, Abramovits W, Rottinghaus ST, Tan H, Gardner A, et al. T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment. J Am Acad Dermatol. 2018;78:1149\u201355.","journal-title":"J Am Acad Dermatol"},{"key":"1883_CR25","doi-asserted-by":"publisher","first-page":"R171","DOI":"10.1186\/ar4358","volume":"15","author":"MC Kapetanovic","year":"2013","unstructured":"Kapetanovic MC, Saxne T, J\u00f6nsson G, Truedsson L, Geborek P. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther. 2013;15:R171.","journal-title":"Arthritis Res Ther"},{"key":"1883_CR26","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1002\/art.30580","volume":"63","author":"MC Kapetanovic","year":"2011","unstructured":"Kapetanovic MC, Roseman C, J\u00f6nsson G, Truedsson L, Saxne T, Geborek P. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum. 2011;63:3723\u201332.","journal-title":"Arthritis Rheum"},{"key":"1883_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.vaccine.2016.12.068","volume":"35","author":"MC Kapetanovic","year":"2017","unstructured":"Kapetanovic MC, Nagel J, Nordstr\u00f6m I, Saxne T, Geborek P, Rudin A. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine. 2017;35:903\u20138.","journal-title":"Vaccine."},{"key":"1883_CR28","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1128\/CVI.00086-12","volume":"19","author":"RL Burton","year":"2012","unstructured":"Burton RL, Nahm MH. Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20. Clin Vaccine Immunol. 2012;19:835\u201341.","journal-title":"Clin Vaccine Immunol"},{"key":"1883_CR29","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s10156-013-0601-1","volume":"19","author":"JY Song","year":"2013","unstructured":"Song JY, Mosely MA, Burton RL, Nahm MH. Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother. 2013;19:412\u201325.","journal-title":"J Infect Chemother"},{"key":"1883_CR30","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","volume":"17","author":"RG Newcombe","year":"1998","unstructured":"Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857\u201372.","journal-title":"Stat Med"},{"key":"1883_CR31","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s10067-011-1856-5","volume":"30","author":"MC Kapetanovic","year":"2011","unstructured":"Kapetanovic MC, Roseman C, Jonsson G, Truedsson L. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs. Clin Rheumatol. 2011;30:1555\u201361.","journal-title":"Clin Rheumatol"},{"key":"1883_CR32","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jbspin.2015.10.017","volume":"83","author":"E R\u00e1k\u00f3czi","year":"2016","unstructured":"R\u00e1k\u00f3czi E, Perge B, V\u00e9gh E, Csomor P, Pusztai A, Szamosi S, et al. Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept. Joint Bone Spine. 2016;83:675\u20139.","journal-title":"Joint Bone Spine"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1883-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1883-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1883-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T23:46:10Z","timestamp":1587080770000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1883-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,18]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1883"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1883-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,18]]},"assertion":[{"value":"7 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was designed by the sponsor, Eli Lilly and Company, an academic advisory board that included non-Lilly authors of this manuscript, and Incyte Corp. The study was conducted in accordance with ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by Quorum Review IRB (#28020). Ethics approvals were obtained for all study sites, up to 405, in this on-going long-term extension study. All patients provided written informed consent for both the long-term extension study as well as the vaccine sub-study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KLW is a consultant for AbbVie, Amgen, BMS, Eli Lilly and Company, Pfizer, and UCB and has received grants from BMS and Pfizer. COB is a consultant for Eli Lilly and Company. WJK, JB, MI, and CEK are employees and stockholders of Eli Lilly and Company. RK is an employee of IQVIA, with which Eli Lilly and Company contracts for statistical support.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"102"}}